Phase II Study of GTx024 in Women With Metastatic Breast Cancer

Summary

The primary efficacy analysis will be the clinical benefit at 6 months as measured by a modified Response Evaluation Criteria in Solid Tumors RECIST classification. Key secondary endpoints of objective response rate, progression free survival, time to progression, duration of response, effects on physical function, and effects on tumor progression in women with Androgen Receptor positive breast cancer will also be assessed.

Timeline

Start

2013-04

Primary completion

2014-06

Completion

2016-03

Drugs

Indications